SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

SYRE

Spyre Therapeutics, Inc.
NASDAQHealth Care

Latest close: 79.90 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Oct 7, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Oct 1, 2026Reported sale · Form 4Scott L Burrows, Chief Financial Officer · $53.4KOpen the filing ↗
  3. Oct 1, 2026Reported sale · Form 4Scott L Burrows, Chief Financial Officer · $135.4KOpen the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record76922 flagged findings
Reported transactions (Form 4)80since Jan 15, 2025 · and 15 other holdings
Corporate events (8-K)30since Jul 14, 2023

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

Identity

Formerly traded as AGLE.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-05-05share offering or dilution eventrecentOpen filing ↗
    “…) The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Spyre Therapeutics, Inc.…”
    +1 more passage from the same document
    • “…vest and become exercisable in 36 equal monthly installments, subject to Mr. McKenna’s continued service to the Company…”
  • 2026-05-05listing compliance noticerecentOpen filing ↗
    “…and financial compliance costs and causes management and other personnel to divert attention from operational and other business…”
  • 2026-04-16share offering or dilution eventrecentOpen filing ↗
    “…to sell, pledge, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any…”
    +1 more passage from the same document
    • “…commitment as indicated in the table above. No Sales of Similar Securities We and our executive officers and directors have…”
  • 2026-04-16capital return (buybacks/dividends)recentOpen filing ↗
    “…the amount of debt securities of such series whose holders must consent to an amendment, supplement or waiver; • reduce the rate of…”
  • 2026-04-13share offering or dilution eventrecentOpen filing ↗
    “…to sell, pledge, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any…”
    +1 more passage from the same document
    • “…commitment as indicated in the table above. No Sales of Similar Securities We and our executive officers and directors have…”
  • 2026-04-13capital return (buybacks/dividends)recentOpen filing ↗
    “…the amount of debt securities of such series whose holders must consent to an amendment, supplement or waiver; • reduce the rate of…”

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

Reverse splits in 5 years

1 reverse split in 5 years (1:25 on Sep 8, 2023) · 1:25 cumulative

The other times: of 818 securities that did their first reverse split in 5 years, a year later the median was worth 0.53× the price on the day of the split; 382 lost more than half and 209 rose (809 with a price a year later).

Our own series, not the whole market: based on the splits we have on record (provider and SEC); an unrecorded one does not count. Historical distribution, not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 769)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Oct 9, 26SCHEDULE 13D/A ↗Stake with intent to influence · Harwin Peter Evan · 10.0% · event on Oct 7, 26 · amendment
  • Oct 7, 268-K ↗Current report · Entered a material agreement
  • Oct 6, 26424B5 ↗Securities offering
  • Oct 5, 26424B5 ↗Securities offering
  • Insider transaction · 3 Form 4 filingsshow all 3hide
  • Notice of proposed sale · 2 Form 144 filingsshow all 2hide
  • Oct 1, 26SCHEDULE 13G ↗Passive stake · Paradigm BioCapital Advisors LP · 5.1% · event on Sep 24, 26
  • Sep 30, 26Form 144 ↗Notice of proposed sale
  • Sep 8, 268-K ↗Current report · Communication to the market · Other events
  • Insider transaction · 3 Form 4 filingsshow all 3hide
  • Sep 1, 26Form 144 ↗Notice of proposed sale
  • Aug 25, 268-K ↗Current report · Communication to the market · Other events
  • Aug 14, 26SCHEDULE 13G/A ↗Passive stake · RTW Investments, LP · 4.8% · event on Jun 30, 26 · amendment
  • Aug 14, 26SCHEDULE 13G/A ↗Passive stake · Perceptive Advisors LLC · 4.9% · event on Jun 30, 26 · amendment
  • Aug 10, 26Form 4 ↗Insider transaction
  • Notice of proposed sale · 2 Form 144 filingsshow all 2hide
  • Insider transaction · 2 Form 4 filingsshow all 2hide
  • Aug 4, 268-K ↗Current report · Results

769 filings on record, the oldest from Jun 3, 15.

Listing the 25 most recent filings of the 769 on record.

8-Ks, explained

Stress7Structure34Governance32
  • Oct 7, 26StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • May 29, 26GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Apr 16, 26StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Oct 15, 25StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Mar 6, 25GovernanceAuditor change filing (8-K Item 4.01)+1 more in the same filing8-K 4.01 ↗
  • Nov 19, 24StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Nov 18, 24StressPast accounts declared unreliable and being restated+1 more in the same filing8-K 4.02 ↗
  • Oct 15, 24StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗
  • May 15, 24StructureEntered a material agreement+5 more in the same filing8-K 1.01 ↗
  • Apr 25, 24StructureSold unregistered shares+1 more in the same filing8-K 3.02 ↗
  • Mar 18, 24StructureEntered a material agreement+4 more in the same filing8-K 1.01 ↗
  • Feb 5, 24StructureEntered a material agreement+4 more in the same filing8-K 1.01 ↗

10 older filings not shown · The record reaches back to Feb 16, 17.

Notable in the record

Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.

  • Jan 18, 24StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Sep 25, 23StressListing notice (8-K 3.01)+3 more in the same filing8-K 3.01 ↗
  • Jul 14, 23StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Apr 12, 23StressRestructuring plan with committed costs+3 more in the same filing8-K 2.05 ↗
  • Jan 18, 23StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Jul 19, 22StressListing notice (8-K 3.01)8-K 3.01 ↗

The full record holds 7 stress filings.

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13D: stake and stated purpose

Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.

  • Harwin Peter Evan10.0%Oct 7, 26SCHEDULE 13D/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
  • Peter Evan Harwin10.0%Jun 23, 26SCHEDULE 13D/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • Peter Harwin10.0%Apr 16, 26SCHEDULE 13D/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum.

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • BlackRock, Inc.6.6%Jun 30, 25SCHEDULE 13G/A ↗
  • Paradigm BioCapital Advisors LP5.1%Sep 24, 26SCHEDULE 13G ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
  • The Vanguard Group5.1%Jun 30, 25SCHEDULE 13G ↗
  • Perceptive Advisors LLC4.9%Jun 30, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
  • RTW Investments, LP4.8%Jun 30, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
show 2 more holdershide
  • Venrock Healthcare Capital Partners III, L.P.4.6%Dec 31, 24SCHEDULE 13G/A ↗7 co-filers on this document — the figure is the largest single stake, not their sum.
  • TANG CAPITAL MANAGEMENT, LLC2.4%Dec 31, 25SCHEDULE 13G/A ↗6 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

Sale intention announced

On Oct 1, CAMERON TURTLE filed notice of intent to sell up to $4.0M. That is about 0.05% of shares outstanding. It is filed under a scheduled plan (10b5-1), arranged in advance.

A notice is not a sale: it may not go ahead, may happen in part, or at a different price.

After the notice, they sold $1.4M across 6 trades on Oct 1, per their Form 4. That is 33% of the shares announced so far, and the window is still open.

View notice (Form 144) ↗+9 more recent notices · 8 with a later sale

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Oct 1, 26Sell$53KScott L BurrowsChief Financial Officer↗
  • Oct 1, 26Sell$135KScott L BurrowsChief Financial Officer↗
  • Oct 1, 26Sell$193KScott L BurrowsChief Financial Officer↗
  • Oct 1, 26Sell$285KScott L BurrowsChief Financial Officer↗
  • Oct 1, 26Sell$21KScott L BurrowsChief Financial Officer↗
  • Oct 1, 26Sell$53KCameron TurtleChief Executive Officer↗
  • Oct 1, 26Sell$242KCameron TurtleChief Executive Officer↗
  • Oct 1, 26Sell$241KCameron TurtleChief Executive Officer↗
  • Oct 1, 26Sell$368KCameron TurtleChief Executive Officer↗
  • Oct 1, 26Sell$466KCameron TurtleChief Executive Officer↗
  • Oct 1, 26Sell$9KCameron TurtleChief Executive Officer↗
  • Oct 1, 26Sell$36KHeidy King-JonesSee Remarks↗

There are 21 more transactions in this stretch.

Stock compensation, tax and giftsshow the 7 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Oct 1, 26Compensation$109KScott L BurrowsChief Financial Officer↗
  • Oct 1, 26Compensation$420KHeidy King-JonesSee Remarks↗
  • Sep 30, 26Compensation$254KScott L BurrowsChief Financial Officer↗
  • Sep 2, 26Compensation$6KHeidy King-JonesSee Remarks↗
  • Sep 1, 26Compensation$109KScott L BurrowsChief Financial Officer↗
  • Sep 1, 26Compensation$406KHeidy King-JonesSee Remarks↗
  • Aug 7, 26Compensation$52KJeffrey W. Albers↗

The full record holds 130 transactions and goes back to Nov 14, 22.

Its sector and its market

Spyre Therapeutics, Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Spyre Therapeutics, Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Spyre Therapeutics, Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
250 clean closes in the period.
SEC records
769 documents on file, from Jun 3, 2015 to Oct 9, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.